10 Best Stocks to Buy for the Next 15 Years
On May 7, Fundstrat’s Tom Lee joined 'Closing Bell' on CNBC to discuss his outlook on the current stock market rally.
Abbvie Inc. (ABBV)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Fisher Asset Management Ken Fisher | 9,092,054 | $1,977,430,921 | +1348% | 0.67% |
| 2. | Leucadia National Ian Cumming And Joseph Steinberg | 208,359 | $45,316,000 | +102% | 0.31% |
| 3. | Lee Munder Capital Group Lee Munder | 136,494 | $29,686,080 | -3% | 1.77% |
| 4. | Polaris Capital Management Bernard Horn | 116,677 | $25,376,081 | -3% | 2.08% |
| 5. | Hourglass Capital Kenneth A. Moffet | 34,070 | $7,409,884 | -13% | 1.54% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $69.00 | 1,550 | $106,950.00 | 17,644 | 2020-03-20 | Filing | |
| $69.00 | 750 | $51,750.00 | 16,844 | 2020-03-20 | Filing | |
| $67.50 | 800 | $54,000.00 | 16,094 | 2020-03-20 | Filing | |
| $68.18 | 2,200 | $150,004.80 | 15,294 | 2020-03-18 | Filing | |
| $69.00 | 750 | $51,750.00 | 16,844 | 2020-03-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $233.56 | 5,230 | $1,221,518.80 | 2,654 | 2026-03-04 | Filing | |
| $235.26 | 2,600 | $611,676.00 | 4,619 | 2026-03-02 | Filing | |
| $234.66 | 10,291 | $2,414,886.06 | 7,219 | 2026-03-02 | Filing | |
| $233.51 | 5,777 | $1,348,987.27 | 17,510 | 2026-03-02 | Filing | |
| $230.00 | 22,381 | $5,147,630.00 | 38,137 | 2026-02-25 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 114,880,324 | $24,985,321,667 | 0.63% | |
| 2. | 49,523,078 | $10,770,774,234 | 0.57% | |
| 3. | 14,051,196 | $3,055,994,618 | 0.46% | |
| 4. | 13,278,161 | $2,887,867,387 | 0.53% | |
| 5. | 12,159,427 | $2,644,553,778 | 0.61% |
News See All
Is AbbVie Inc. (ABBV) One of the Best Drug Stocks to Buy According to Analysts?
AbbVie Inc. (NYSE:ABBV) is one of the best drug stocks to buy according to analysts. AbbVie Inc. (NYSE:ABBV) announced on April 27 the submission of an application to the U.S.
10 Best Large Cap Dividend Growth Stocks to Invest In
Dividends don’t always get much attention, but they’ve quietly driven a large share of long-term returns.
AbbVie Inc. (NYSE:ABBV) Q1 2026 Earnings Call Transcript
Operator: Good morning, and thank you for standing by. Welcome to the AbbVie First Quarter 2026 Earnings Conference Call. [Operator Instructions] Today's call is also being recorded.
10 Best Quality Dividend Stocks to Buy According to Reddit
Retail investors have taken center stage in 2026. Scott Rubner of Citadel Securities noted that trading activity from individual investors hit a record in January.
Piper Sandler Cuts PT on AbbVie Inc. (ABBV) Ahead of Quarterly Results
AbbVie Inc. (NYSE:ABBV) is one of the best stem cell therapy stocks to buy. On April 23, Piper Sandler cut the price target on AbbVie Inc.
AbbVie Inc. (ABBV) Receives CRL from the FDA About the Biologics License Application for trenibotulinumtoxinE
AbbVie Inc. (NYSE:ABBV) is one of the best low volatility stocks to invest in right now. AbbVie Inc. (NYSE:ABBV) announced on April 23 that it received a Complete Response Letter (CRL) from the U.S.
8 Best Low Volatility Stocks to Invest In Right Now
On April 23, Peter Boockvar, One Point BFG Wealth Partners CIO, appeared on CNBC’s ‘Fast Money’ to talk about the market dynamics.
8 Best Stem Cell Therapy Stocks to Buy
He stated that he is not surprised at the market resilience in the face of risk factors such as the war, oil prices, and inflation, looking at the behavior of the S&P 500 and the equity market more broadly...
Top 30 S&P 500 Stocks by Index Weight
It’s been a turbulent year for the S&P 500 amid heightened volatility, driven by monetary policy uncertainty and inflationary concerns, and exacerbated by geopolitical tensions.
Hedge Fund Resource Center